FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2564295907> ?p ?o ?g. }

• W2564295907 abstract "Abstract Abstract 1072 Background: Children with acute myeloid leukemia (AML) may present with high white blood cell counts (WBC). While it is well known that hyperleukocytosis is associated with leukostasis and tumor lysis syndrome, precise estimates of incidence of associated complications and death rates during induction are lacking from homogenously treated children with contemporary supportive care. The Children's Oncology Group (COG) adopted a modified AML Medical Research Council backbone and reviewed adverse event reports in real time to optimize accurate toxicity data. From August 14, 2006 to March 31, 2010, COG AAML0531 randomized 968 children and young adults with de novo AML to gemtuzumab ozogamicin (GMTZ) versus no GMTZ. The objectives in this report were to describe the prevalence of hyperleukocytosis as defined as an initial WBC ≥ 100×109/L and its association with incidence of metabolic, pulmonary and central nervous system (CNS) toxicities and the rate of Induction I deaths. Methods: AAML0531 included those ≥ 1 month to ≤ 30 years with de novo AML and used a 5 cycle chemotherapy regimen. Induction I consisted of cytarabine, daunorubicin, and etoposide (ADE 10+3+5). All Common Terminology Criteria for Adverse Events v3.0 ≥ grade 3 toxicities were collected prospectively. Results: Among the 968 children, initial WBC was available for 923 patients. Of these, 744 (80.6%) had an initial WBC < 100×109/L and 179 (19.4%) had an initial WBC ≥ 100×109/L. The Table illustrates the prevalence of metabolic, pulmonary and CNS ≥ grade 3 toxicities during Induction I. Hyperkalemia, high creatinine and hyperuricemia were generally rare. Higher initial WBC was significantly associated with hyperuricemia (P=0.005) and severe high creatinine (P=0.009). No significant differences in hyperphosphatemia or hyperkalemia were seen according to the initial WBC. The prevalence of hypoxia was 30.8% among the 13 children with an initial WBC ≥ 400×109/L and higher initial WBC was significantly associated with more hypoxia (P<0.001) and pulmonary hemorrhage (P<0.001). While CNS ischemia or hemorrhage occurred in 5.3% of children with an initial WBC ≥ 300 to < 400×109/L and 7.7% with an initial WBC ≥ 400×109/L, seizures were not reported for these patients with extremely elevated initial WBC. CNS ischemia/hemorrhage was significantly associated with increasing initial WBC (P<0.001) while there was no association between seizures and WBC. Deaths during Induction I occurred in 10.5% of those with initial WBC ≥ 300 to < 400×109/L and 15.4% of those with an initial WBC ≥ 400×109/L. The Induction I death rate was significantly higher with higher initial WBC (P=0.005). Conclusions: Almost 20% of newly diagnosed children with AML have hyperleukocytosis. With contemporary supportive care and homogenous AML therapy, tumor lysis syndrome is uncommon and hyperkalemia is no longer affected by high initial WBC although hyperuricemia and acute renal failure still occur in spite of contemporary supportive care. In addition, pulmonary toxicities in terms of hypoxia and pulmonary hemorrhage as well as CNS ischemia/hemorrhage remain problematic with increasing risk by initial WBC. At least 10 to 15% of patients with an initial WBC ≥ 300 × 109/L died during their first chemotherapy cycle and thus, strategies to improve outcomes related to pulmonary toxicity and CNS injury in hyperleukocytosis are important future goals. Disclosures: Smith: Pfizer, Inc: Member, Medical Advisory Committee (for bosutinib, not GO)." @default.
• W2564295907 created "2017-01-06" @default.
• W2564295907 creator A5008703987 @default.
• W2564295907 creator A5012776569 @default.
• W2564295907 creator A5014175965 @default.
• W2564295907 creator A5020000300 @default.
• W2564295907 creator A5021003209 @default.
• W2564295907 creator A5031290819 @default.
• W2564295907 creator A5035790918 @default.
• W2564295907 creator A5037359116 @default.
• W2564295907 creator A5048708937 @default.
• W2564295907 creator A5049490094 @default.
• W2564295907 creator A5053592964 @default.
• W2564295907 creator A5060816563 @default.
• W2564295907 creator A5066861312 @default.
• W2564295907 creator A5071304194 @default.
• W2564295907 creator A5073322914 @default.
• W2564295907 creator A5086900250 @default.
• W2564295907 date "2010-11-19" @default.
• W2564295907 modified "2023-09-30" @default.
• W2564295907 title "High Mortality In Extreme Hyperleukocytosis In Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group." @default.
• W2564295907 doi "https://doi.org/10.1182/blood.v116.21.1072.1072" @default.
• W2564295907 hasPublicationYear "2010" @default.
• W2564295907 type Work @default.
• W2564295907 sameAs 2564295907 @default.
• W2564295907 citedByCount "0" @default.
• W2564295907 crossrefType "journal-article" @default.
• W2564295907 hasAuthorship W2564295907A5008703987 @default.
• W2564295907 hasAuthorship W2564295907A5012776569 @default.
• W2564295907 hasAuthorship W2564295907A5014175965 @default.
• W2564295907 hasAuthorship W2564295907A5020000300 @default.
• W2564295907 hasAuthorship W2564295907A5021003209 @default.
• W2564295907 hasAuthorship W2564295907A5031290819 @default.
• W2564295907 hasAuthorship W2564295907A5035790918 @default.
• W2564295907 hasAuthorship W2564295907A5037359116 @default.
• W2564295907 hasAuthorship W2564295907A5048708937 @default.
• W2564295907 hasAuthorship W2564295907A5049490094 @default.
• W2564295907 hasAuthorship W2564295907A5053592964 @default.
• W2564295907 hasAuthorship W2564295907A5060816563 @default.
• W2564295907 hasAuthorship W2564295907A5066861312 @default.
• W2564295907 hasAuthorship W2564295907A5071304194 @default.
• W2564295907 hasAuthorship W2564295907A5073322914 @default.
• W2564295907 hasAuthorship W2564295907A5086900250 @default.
• W2564295907 hasConcept C10205521 @default.
• W2564295907 hasConcept C126322002 @default.
• W2564295907 hasConcept C143998085 @default.
• W2564295907 hasConcept C176290653 @default.
• W2564295907 hasConcept C187212893 @default.
• W2564295907 hasConcept C197934379 @default.
• W2564295907 hasConcept C2776611710 @default.
• W2564295907 hasConcept C2776694085 @default.
• W2564295907 hasConcept C2777432695 @default.
• W2564295907 hasConcept C2777793932 @default.
• W2564295907 hasConcept C2778041864 @default.
• W2564295907 hasConcept C2778119113 @default.
• W2564295907 hasConcept C2778336483 @default.
• W2564295907 hasConcept C2778461978 @default.
• W2564295907 hasConcept C2778488018 @default.
• W2564295907 hasConcept C2778623314 @default.
• W2564295907 hasConcept C2778729363 @default.
• W2564295907 hasConcept C2779788671 @default.
• W2564295907 hasConcept C2781413609 @default.
• W2564295907 hasConcept C28328180 @default.
• W2564295907 hasConcept C54355233 @default.
• W2564295907 hasConcept C71924100 @default.
• W2564295907 hasConcept C86803240 @default.
• W2564295907 hasConceptScore W2564295907C10205521 @default.
• W2564295907 hasConceptScore W2564295907C126322002 @default.
• W2564295907 hasConceptScore W2564295907C143998085 @default.
• W2564295907 hasConceptScore W2564295907C176290653 @default.
• W2564295907 hasConceptScore W2564295907C187212893 @default.
• W2564295907 hasConceptScore W2564295907C197934379 @default.
• W2564295907 hasConceptScore W2564295907C2776611710 @default.
• W2564295907 hasConceptScore W2564295907C2776694085 @default.
• W2564295907 hasConceptScore W2564295907C2777432695 @default.
• W2564295907 hasConceptScore W2564295907C2777793932 @default.
• W2564295907 hasConceptScore W2564295907C2778041864 @default.
• W2564295907 hasConceptScore W2564295907C2778119113 @default.
• W2564295907 hasConceptScore W2564295907C2778336483 @default.
• W2564295907 hasConceptScore W2564295907C2778461978 @default.
• W2564295907 hasConceptScore W2564295907C2778488018 @default.
• W2564295907 hasConceptScore W2564295907C2778623314 @default.
• W2564295907 hasConceptScore W2564295907C2778729363 @default.
• W2564295907 hasConceptScore W2564295907C2779788671 @default.
• W2564295907 hasConceptScore W2564295907C2781413609 @default.
• W2564295907 hasConceptScore W2564295907C28328180 @default.
• W2564295907 hasConceptScore W2564295907C54355233 @default.
• W2564295907 hasConceptScore W2564295907C71924100 @default.
• W2564295907 hasConceptScore W2564295907C86803240 @default.
• W2564295907 hasLocation W25642959071 @default.
• W2564295907 hasOpenAccess W2564295907 @default.
• W2564295907 hasPrimaryLocation W25642959071 @default.
• W2564295907 hasRelatedWork W120624340 @default.
• W2564295907 hasRelatedWork W1835210804 @default.
• W2564295907 hasRelatedWork W1992647163 @default.
• W2564295907 hasRelatedWork W1994822649 @default.
• W2564295907 hasRelatedWork W2061339243 @default.
• W2564295907 hasRelatedWork W2103092809 @default.
• W2564295907 hasRelatedWork W2146322615 @default.
• W2564295907 hasRelatedWork W2181971197 @default.

• next